Reimbursement for expensive immune globulin (IG) therapies can be challenging and frustrating for providers. Here's a guide to help ensure they are reimbursed for the cost of these medications.
Healthcare costs continue to rise and payment models subsequently evolve, payers nevertheless largely decide which expensive high-investment drugs will be reimbursed and under what circumstances.
Demand for IG products has doubled, going from 3 million grams just a decade ago to 7 million grams year-over-year today. What is to account for this increase?
One baby born every hour dependent on opiate drugs; treatment is difficult, and health impacts can be lifelong.
As baby boomers age, rates of cancer diagnosis and survival increase, causing an increasing need for supportive oncology care.
Knowing the facts about shingles can help you to better protect yourself against it — and how to treat it if you get it.
Toxic shock syndrome remains a serious, life-threatening complication of certain types of infections that can be fatal.
Using nutrition to benefit health through the care and feeding of genes, though still in its infancy, is an exciting field of study seeing exponential growth.
Despite the many vaccine candidates undergoing clinical trials, experts doubt an effective vaccine for Alzheimer's disease is on the horizon.
Healthcare professionals who do not embrace AI will eventually find themselves out of touch with the industry.
New FcRn inhibitors may be a viable therapeutic option for certain patients currently treated withIG and plasma exchange.
To appreciate how the “Chinese economic miracle” has helped improve access in particular to advanced medical care, one need look no further than its utilization of a single product that is widely used in hospitals to treat severely ill intensive care unit and other patients. That product, now China’s highest dollar-value prescribed therapeutic, is human albumin.
